FORTRESS BIOTECH ANNOUNCES AN EXCLUSIVE LICENSE AGREEMENT FOR FB-607 FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D)

Reuters · 1d ago

Please log in to view news